Monopar Therapeutics (MNPR) Reiterated at Overweight by Cantor Fitzgerald

July 15, 2026 7:45 AM

Cantor Fitzgerald analyst Kirsten Kluska reiterated an Overweight rating and $109.00 price target on Monopar Therapeutics (NASDAQ: MNPR)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found